Capricor Therapeutics 与 Nippon Shinyaku 合作，在欧盟/英国分销 DMD 药物 deramiocel，里程碑付款高达 $715M 和利润分享。 Capricor Therapeutics partners with Nippon Shinyaku for EU/UK distribution of DMD drug deramiocel, with milestone payment up to $715M and profit sharing.
Capricor Therapeutics 已与日本 Nippon Shinyaku Co.， Ltd. 合作，在欧洲商业化和分销其治疗杜氏肌营养不良症的药物 deramiocel。 Capricor Therapeutics has partnered with Japan's Nippon Shinyaku Co., Ltd. to commercialize and distribute its drug deramiocel for Duchenne muscular dystrophy in Europe. 该协定包括预付2 000万美元、里程碑付款7.15亿美元和产品收入份额。 The agreement includes a $20 million upfront payment, up to $715 million in milestone payments, and a share of product revenue. Nippon Shinyaku 将负责欧盟和英国的销售，而 Capricor 将负责开发和制造。 Nippon Shinyaku will handle sales in the EU and U.K., while Capricor will manage development and manufacturing. 这笔交易旨在支持毒品在高需求市场的潜在启动。 The deal aims to support the drug's potential launch in a high-demand market.